title: Conformal radiotherapy for unresectable retroperitoneal soft tissue sarcoma.
abstract: Local tumor control remains a continuing challenge in the treatment of retroperitoneal soft tissue sarcoma. Though complete resection by means of wide excision or excisional biopsy can be performed in a minority of patients only, aggressive surgical approach remains the treatment of choice. Unresectable sarcoma can rarely be controlled by conventionally applied radiotherapy--only a few percent of patients survive. A superior dose distribution of external radiation is demanded in order to spare healthy tissue. The presumably greatest advantage will occur when radiotherapy is used preoperatively. The possible clinical gain of superior dose distribution is demonstrated by results of the dynamic, 3-D conformal pion radiotherapy at PSI. Between April 1983 and June 1988 a total of 21 patients were treated with high doses (greater than or equal to 30 Gy) for unresectable retroperitoneal soft tissue sarcoma. The follow-up time is 13-74 months, median 24. Fifteen patients were treated with 20 fx, and 19 patients were treated with fraction sizes of 150 or 165 cGy. Except for one patient with thrombocytopenia after chemotherapy, no treatment interruption was necessary. Five patients developed late reactions, caused also by surgery and chemotherapy: two intestinal obstructions, one liver abscess, one leg edema, and one superficial skin necrosis. Nine patients had laparotomy after pion irradiation, five for resection of the previous unresectable tumor; 3/5 sarcoma were completely resected. Morbidity rate after post-pion laparotomy did not increase. Three patients had local tumor progression, 1/3 inside the treatment volume. The actuarial five-year local tumor control rate of these unresectable retroperitoneal sarcoma is 60%, the actuarial five-year survival rate is 33%. Out of the 21 patients, 15 are alive, two have died from local progression, one from peritoneal progression, and three from metastases.
authors.affiliation: Paul Scherrer Institute (PSI), Division of Radiation Medicine, Villigen-PSI, Switzerland.
authors.forename: R H
authors.initials: RH
authors.lastname: Greiner
authors.forename: G
authors.initials: G
authors.lastname: Munkel
authors.forename: H
authors.initials: H
authors.lastname: Blattmann
authors.forename: A
authors.initials: A
authors.lastname: Coray
authors.forename: R
authors.initials: R
authors.lastname: Kann
authors.forename: E
authors.initials: E
authors.lastname: Pedroni
authors.forename: P
authors.initials: P
authors.lastname: Thum
mesh_terms: D006801:Humans; D008651:Mesons; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012186:Retroperitoneal Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000532:radiotherapy*; D012189:Retrospective Studies; D012509:Sarcoma / Q000453:epidemiology / Q000401:mortality / Q000532:radiotherapy*; D012983:Soft Tissue Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate; D013557:Switzerland / Q000453:epidemiology